Nutra Pharma Corp (NPHC) 0.0072 $NPHC
Nutra Pharma Announces Laboratory Recertification and Manufacturing Updates
Marketwired - Wed Nov 12, 7:32AM CST
Nutra Pharma Corp. (OTC: NPHC), a biotechnology company that is developing treatments for Adrenomyeloneuropathy (AMN), HIV and Multiple Sclerosis (MS), is announcing the recertification of their Plantation, Florida laboratory facilities. This includes manufacturing, research and production space as well as a clean room module. The recertification allows for the continuing production of their over-the-counter (OTC) pain reliever, Nyloxin(R) and their newest product, Pet Pain-Away; a homeopathic treatment for pain in companion animals. The primary purpose of the laboratory updates, calibrations and certification is to allow the company to re-engage in their clinical platform and to begin eventual trials in their drug pipeline with therapeutic agents for MS, HIV and AMN.
Nutra Pharma Retains BUYINS.NET to Surveil Short Sellers and Market-Makers
Marketwire - Thu Aug 21, 7:30AM CDT
Nutra Pharma Corp (OTC: NPHC)
BUYINS.NET Issues Nutra Pharma (NPHC) SqueezeTrigger Report
M2 - Thu Aug 21, 7:02AM CDT
BUYINS.NET, http://www.buyins.net, a leading provider of Regulation SHO compliance monitoring, short sale trading statistics and market integrity surveillance, has initiated coverage on Nutra Pharma Corp (OTC: NPHC) after releasing the latest short sale data through August 18, 2014. The total aggregate number of shares shorted since August 2009 is approximately 547 million shares. Approximately 32.11% of daily trading volume is short selling. The SqueezeTrigger price for all NPHC shares shorted is $.08. A short squeeze is expected to begin when NPHC closes above the $.08 SqueezeTrigger price.
Nutra Pharma Provides Nyloxin(R) Marketing Updates
Marketwire - Tue Aug 19, 7:02AM CDT
Nutra Pharma Corp. (OTC: NPHC), a biotechnology company that is developing treatments for Adrenomyeloneuropathy (AMN), HIV and Multiple Sclerosis (MS), is announcing updates to the marketing plan for their over-the-counter (OTC) pain reliever, Nyloxin(R). Nutra Pharma previously announced a commercial campaign that began at the end of June 2014. Additional commercials are being produced as well as ongoing support on a weekly radio campaign.
Nutra Pharma Analyst Report by Small Cap Traders and Issued by BrokerBank Securities, Inc.
PR Newswire - Tue Aug 19, 6:00AM CDT
Nutra Pharma Corp. (OTCBB: NPHC) has experienced recurring, significant losses from operations, and has an accumulated deficit of $43,512,705 at June 30, 2014. In addition, it had respective working capital and stockholders' deficits at June 30, 2014 of $3,967,164 and $3,964,165 respectively. There is a substantial doubt regarding Nutra Pharma's ability to continue as a going concern which is contingent upon its ability to secure additional financing, increase ownership equity and attain profitable operation. However, an increase in sales of Nyloxin® during the six month period ended June 2014, along with the steady annual growth rate in the global pain management drug market, can bring relief to offset losses.
Nutra Pharma Announces Infrastructure Improvements to Handle Increased Sales
GlobeNewswire - Thu Jul 24, 7:00AM CDT
Nutra Pharma Corp. (OTCPink:NPHC), a biotechnology company that is developing treatments for Adrenomyeloneuropathy (AMN), HIV and Multiple Sclerosis (MS), is announcing that they are in the process of completing critical capital improvements to their warehouse and fulfillment center in order to meet increased demand and shipments of their over-the-counter (OTC) pain reliever, Nyloxin(R). These improvements include: new rack systems throughout the facility, the purchase of a forklift, new management software as well as hiring additional staff.
Myasthenia Gravis - Pipeline Review, H1 2014
M2 - Thu Jul 03, 5:13AM CDT
Research and Markets (http://www.researchandmarkets.com/research/z232kc/myasthenia_gravis) has announced the addition of the "Myasthenia Gravis - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Myasthenia Gravis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Myasthenia Gravis and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Myasthenia Gravis - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Myasthenia Gravis pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - GlaxoSmithKline plc - Grifols, S.A. - Astellas Pharma Inc. - Nutra Pharma Corporation - Alexion Pharmaceuticals, Inc. - Alnylam Pharmaceuticals, Inc. - Cytokinetics, Inc. - HanAll Biopharma Co., Ltd. - CuraVac, Inc. - Biokine Therapeutics Ltd. - Toleranzia AB For more information visit http://www.researchandmarkets.com/research/z2...nia_gravis
CYTK: 4.23 (-0.01), ALXN: 188.76 (-4.83), GSK: 45.74 (+0.08)
Emerging Market Companies and Investor Updates Provided by BrokerBank Securities, Inc.
PR Newswire - Thu Jun 26, 6:00AM CDT
NYBD Holding, Inc. (OTCBB: NYBD) has filed for a name change and it has been accepted. The company will now be trading under (AQUA), will be named Pleasant Kids, Inc. and the company is expecting the name and symbol change to take affect within the next few business days.
Nutra Pharma reports airing of OTC Pain Reliever Nyloxin commercials on television
M2 - Thu Jun 26, 5:04AM CDT
Biotechnology company Nutra Pharma (OTC:NPHC) disclosed on Wednesday that MyNyloxin.com has begun airing television commercials of its OTC Pain Reliever Nyloxin to help grow sales and increase public awareness.
Nutra Pharma Announces Nyloxin Television Commercial Rollout
Marketwire - Wed Jun 25, 9:10AM CDT
Nutra Pharma Corp. (OTC: NPHC), a biotechnology company that is developing treatments for Adrenomyeloneuropathy (AMN), HIV and Multiple Sclerosis (MS), is announcing that MyNyloxin.com, a company that has the exclusive rights to market and distribute Nutra Pharma's over-the-counter (OTC) pain reliever, Nyloxin(R), has begun airing television commercials as of Monday, June 23rd. The advertisements focus on the benefits of Nyloxin(R). The first contract has already begun and includes over 30,000 spots to run throughout the Southeast Region from Comcast and AT&T U-Verse Cable providers. The ads are scheduled to run on the following channels: GOLF, LMN, CNBC, FOXN, MSNBC, NBCS, ESPN, ESPN2, TNT, FOXS, TWC, CNN, HALL, HGTV, TLC, HLN and LIFE. Starting June 30, the commercials will begin airing in the New York and New Jersey markets with a rollout to the national stage in the coming weeks.
Nutra Pharma Announces Completion of Commercials by MyNyloxin.com
Marketwire - Wed Jun 25, 8:25AM CDT
Nutra Pharma Corp. (OTC: NPHC), a biotechnology company that is developing treatments for Adrenomyeloneuropathy (AMN), HIV and Multiple Sclerosis (MS), is announcing that MyNyloxin.com, a new company that has the exclusive rights to market and distribute Nutra Pharma's over-the-counter (OTC) pain reliever, Nyloxin(R), in the Network Marketing channel has completed their work on a series of commercials to start airing in the month of June. The advertisements focus on the benefits of Nyloxin(R) and include 30 second, 60 second and 120 second spots.
Global Amyotrophic Lateral Sclerosis Market 2014-2018: Advanced New Discoveries and Treatments Sheds Light on Factors Involved In ALS
M2 - Thu Feb 13, 6:39AM CST
Research and Markets (http://www.researchandmarkets.com/research/3qv6rf/global) has announced the addition of the "Global Amyotrophic Lateral Sclerosis Market 2014-2018" report to their offering. The analysts forecast the Global Amyotrophic Lateral Sclerosis Drugs Market to grow at a CAGR of 5.39 percent over the period 2013-2018. One of the key factors contributing to this market growth is the increasing global aging population. The Global Amyotrophic Lateral Sclerosis Drugs Market has also been witnessing the increasing awareness of ALS drugs. However, the patent expiry of Rilutek could pose a challenge to the growth of this market. Key vendors dominating this space include Covis Pharmaceutical Inc., Eisai Co. Ltd., GlaxoSmithKline plc, and Mitsubishi Tanabe Pharma Corp. Other vendors mentioned in the report are Amorfix Life Sciences Ltd., BrainStrom Cell Therapeutics Inc., Newron Pharmaceuticals S.p.A, Neuraltus Pharmaceuticals Inc., Nutra Pharma Corp., Oxford BioMedica plc, Pharnext SAS, and Q-Therapeutics Inc. Commenting on the report, an analyst from the team said: The acceptability of ALS drugs is expected to rise due to increasing public awareness of ALS and associated disorders. This is expected to result in increasing drug penetration. Rising general awareness about ALS has led to an increase in research funding and support for clinical and support services. For instance, May is celebrated as ALS awareness month. The ALS Association strives to involve and engage patients and families in the process of increasing awareness and advocating for legislative changes. Similarly, CDMRP also organizes the ALS Research Program. The global research effort through this program has helped increase the number of scientists working on ALS, advanced new discoveries and treatments, and has shed light on the complex genetic and environmental factors involved in ALS. According to the report, one of the main drivers in this market is the increase in the aging population. The number of patients suffering from ALS is increasing due to its relatively high prevalence in the elderly population. For more information visit http://www.researchandmarkets.com/research/3qv6rf/global About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
GSK: 45.74 (+0.08)
New IGP Sets His Priorities, Warns Unethical Officers
by Abdulwakil Saiboko - All Africa Global Media - Thu Jan 09, 10:36PM CST
THE newly-appointed Inspector- General of Police (IGP), Mr Ernest Mangu, has outlined his priorities, warning police over unethical behaviour, saying severe measures will be taken against violators.
SGYP: 3.00 (-0.07), CVM: 0.65 (+0.04), GSK: 45.74 (+0.08), SVA: 5.25 (+0.01), AGEN: 2.98 (unch), VICL: 1.12 (-0.02), FLML: 13.17 (-0.22), MRK: 59.07 (-0.47), NVS: 93.95 (-0.43)
Front Street Energy Growth Fund Inc. Labour Sponsored Fund-Suspension of Redemptions
Marketwire Canada - Fri Dec 20, 1:44PM CST
Due to the 2013 federal government budget announcement that it is discontinuing the Labour Sponsored Venture Capital Corporation ("LSVCC"
program, Front Street Capital 2004 (the "Manager" has announced it is considering options with respect to the labour sponsored fund it manages, Front Street Energy Growth Fund Inc. (the "Fund" .
Nutra Pharma Provides Update on Inventory and Fulfillment
Business Wire - Wed Sep 11, 7:30AM CDT
Nutra Pharma Corporation (OTCQB: NPHC), a biotechnology company that is developing treatments for Multiple Sclerosis (MS), Human Immunodeficiency Virus (HIV), Adrenomyeloneuropathy (AMN) and Pain, announced today that they have completed the process of moving their inventory of their all-natural, non-addictive pain reliever, Nyloxin(R), into their Plantation, Florida facility and that they will be handling fulfillment services in-house.
Amyotrophic Lateral Sclerosis - Pipeline Review, H2 2013 comes Complete with Latest Updates
M2 - Thu Sep 05, 10:04AM CDT
Research and Markets (http://www.researchandmarkets.com/research/kg6q26/amyotrophic) has announced the addition of the "Amyotrophic Lateral Sclerosis - Pipeline Review, H2 2013" report to their offering. Global Markets Direct's, 'Amyotrophic Lateral Sclerosis - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Amyotrophic Lateral Sclerosis and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Amyotrophic Lateral Sclerosis. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - A snapshot of the global therapeutic scenario for Amyotrophic Lateral Sclerosis. - A review of the Amyotrophic Lateral Sclerosis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Amyotrophic Lateral Sclerosis pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Mentioned: - Aeolus Pharmaceuticals, Inc. - Amorfix Life Sciences Ltd. - Biogen Idec Inc. - BrainStorm Cell Therapeutics Inc. - California Stem Cell, Inc. - Cellceutix Corporation - Ceregene, Inc. - Cytokinetics, Inc - D-Pharm Ltd. - Daval International Ltd. - Eisai Co., Ltd. - Genzyme Corporation - GlaxoSmithKline plc - Hadasit Medical Research Services & Development Ltd - Isis Pharmaceuticals, Inc. - Isotechnika Pharma Inc. - Jeil Pharmaceutical Co., Ltd. - KineMed, Inc. - Kringle Pharma, Inc. - M's Science Corporation - Maas Biolab - MediPost Co., Ltd. - miRagen Therapeutics, Inc. - Mitsubishi Tanabe Pharma Corporation - Neuralstem, Inc. - Neuraltus Pharmaceuticals, Inc. - Neurimmune Therapeutics AG - NeuroNova AB - Nexgenix Pharmaceuticals, LLC - Novartis AG - Nutra Pharma Corporation - Oxford BioMedica plc - Paladin Labs Inc. - Pharmagenesis, Inc. - Pharnext SAS - Q Therapeutics, Inc. - Questcor Pharmaceuticals, Inc. - Reata Pharmaceuticals, Inc. - RhinoCyte, Inc. - SCYNEXIS, Inc. - Snowdon Inc. - Trophos SA - Varinel, Inc. For more information visit http://www.researchandmarkets.com/research/kg...myotrophic About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
CYTK: 4.23 (-0.01), BIIB: 305.43 (-12.55), GSK: 45.74 (+0.08), BCLI: 3.47 (-0.11), QCOR: 93.60 (+1.52), ISIS: 49.01 (-1.70), NVS: 93.95 (-0.43), CUR: 2.86 (+0.05)
Nutra Pharma Announces Delivery of Nyloxin(TM) to New Vitality
Business Wire - Thu Aug 29, 7:30AM CDT
Nutra Pharma Corporation (OTCQB:NPHC), a biotechnology company that is developing treatments for Multiple Sclerosis (MS), Human Immunodeficiency Virus (HIV), Adrenomyeloneuropathy (AMN) and Pain, announced today that New Vitality, a marketing and distribution company, has placed and received their first order of the Company's all-natural, non-addictive pain reliever, Nyloxin(R). The order was pursuant to New Vitality's successful test radio campaign to gauge the market acceptance of the product.
Nutra Pharma Corporation begins registration process in South Africa of homeopathic pain drug Nyloxin
M2 - Fri Aug 23, 4:09AM CDT
Biotechnology company Nutra Pharma Corporation (OTC Markets:NPHC) reported on Thursday the start of the registration process in South Africa of its homeopathic chronic pain drug Nyloxin.
Nutra Pharma Announces Laboratory Recertification and Manufacturing Updates
Marketwired - Wed Nov 12, 7:32AM CST
Nutra Pharma Corp. (OTC: NPHC), a biotechnology company that is developing treatments for Adrenomyeloneuropathy (AMN), HIV and Multiple Sclerosis (MS), is announcing the recertification of their Plantation, Florida laboratory facilities. This includes manufacturing, research and production space as well as a clean room module. The recertification allows for the continuing production of their over-the-counter (OTC) pain reliever, Nyloxin(R) and their newest product, Pet Pain-Away; a homeopathic treatment for pain in companion animals. The primary purpose of the laboratory updates, calibrations and certification is to allow the company to re-engage in their clinical platform and to begin eventual trials in their drug pipeline with therapeutic agents for MS, HIV and AMN.
Nutra Pharma Retains BUYINS.NET to Surveil Short Sellers and Market-Makers
Marketwire - Thu Aug 21, 7:30AM CDT
Nutra Pharma Corp (OTC: NPHC)
BUYINS.NET Issues Nutra Pharma (NPHC) SqueezeTrigger Report
M2 - Thu Aug 21, 7:02AM CDT
BUYINS.NET, http://www.buyins.net, a leading provider of Regulation SHO compliance monitoring, short sale trading statistics and market integrity surveillance, has initiated coverage on Nutra Pharma Corp (OTC: NPHC) after releasing the latest short sale data through August 18, 2014. The total aggregate number of shares shorted since August 2009 is approximately 547 million shares. Approximately 32.11% of daily trading volume is short selling. The SqueezeTrigger price for all NPHC shares shorted is $.08. A short squeeze is expected to begin when NPHC closes above the $.08 SqueezeTrigger price.
Nutra Pharma Provides Nyloxin(R) Marketing Updates
Marketwire - Tue Aug 19, 7:02AM CDT
Nutra Pharma Corp. (OTC: NPHC), a biotechnology company that is developing treatments for Adrenomyeloneuropathy (AMN), HIV and Multiple Sclerosis (MS), is announcing updates to the marketing plan for their over-the-counter (OTC) pain reliever, Nyloxin(R). Nutra Pharma previously announced a commercial campaign that began at the end of June 2014. Additional commercials are being produced as well as ongoing support on a weekly radio campaign.
Nutra Pharma Analyst Report by Small Cap Traders and Issued by BrokerBank Securities, Inc.
PR Newswire - Tue Aug 19, 6:00AM CDT
Nutra Pharma Corp. (OTCBB: NPHC) has experienced recurring, significant losses from operations, and has an accumulated deficit of $43,512,705 at June 30, 2014. In addition, it had respective working capital and stockholders' deficits at June 30, 2014 of $3,967,164 and $3,964,165 respectively. There is a substantial doubt regarding Nutra Pharma's ability to continue as a going concern which is contingent upon its ability to secure additional financing, increase ownership equity and attain profitable operation. However, an increase in sales of Nyloxin® during the six month period ended June 2014, along with the steady annual growth rate in the global pain management drug market, can bring relief to offset losses.
Nutra Pharma Announces Infrastructure Improvements to Handle Increased Sales
GlobeNewswire - Thu Jul 24, 7:00AM CDT
Nutra Pharma Corp. (OTCPink:NPHC), a biotechnology company that is developing treatments for Adrenomyeloneuropathy (AMN), HIV and Multiple Sclerosis (MS), is announcing that they are in the process of completing critical capital improvements to their warehouse and fulfillment center in order to meet increased demand and shipments of their over-the-counter (OTC) pain reliever, Nyloxin(R). These improvements include: new rack systems throughout the facility, the purchase of a forklift, new management software as well as hiring additional staff.
Myasthenia Gravis - Pipeline Review, H1 2014
M2 - Thu Jul 03, 5:13AM CDT
Research and Markets (http://www.researchandmarkets.com/research/z232kc/myasthenia_gravis) has announced the addition of the "Myasthenia Gravis - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Myasthenia Gravis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Myasthenia Gravis and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Myasthenia Gravis - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Myasthenia Gravis pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - GlaxoSmithKline plc - Grifols, S.A. - Astellas Pharma Inc. - Nutra Pharma Corporation - Alexion Pharmaceuticals, Inc. - Alnylam Pharmaceuticals, Inc. - Cytokinetics, Inc. - HanAll Biopharma Co., Ltd. - CuraVac, Inc. - Biokine Therapeutics Ltd. - Toleranzia AB For more information visit http://www.researchandmarkets.com/research/z2...nia_gravis
CYTK: 4.23 (-0.01), ALXN: 188.76 (-4.83), GSK: 45.74 (+0.08)
Emerging Market Companies and Investor Updates Provided by BrokerBank Securities, Inc.
PR Newswire - Thu Jun 26, 6:00AM CDT
NYBD Holding, Inc. (OTCBB: NYBD) has filed for a name change and it has been accepted. The company will now be trading under (AQUA), will be named Pleasant Kids, Inc. and the company is expecting the name and symbol change to take affect within the next few business days.
Nutra Pharma reports airing of OTC Pain Reliever Nyloxin commercials on television
M2 - Thu Jun 26, 5:04AM CDT
Biotechnology company Nutra Pharma (OTC:NPHC) disclosed on Wednesday that MyNyloxin.com has begun airing television commercials of its OTC Pain Reliever Nyloxin to help grow sales and increase public awareness.
Nutra Pharma Announces Nyloxin Television Commercial Rollout
Marketwire - Wed Jun 25, 9:10AM CDT
Nutra Pharma Corp. (OTC: NPHC), a biotechnology company that is developing treatments for Adrenomyeloneuropathy (AMN), HIV and Multiple Sclerosis (MS), is announcing that MyNyloxin.com, a company that has the exclusive rights to market and distribute Nutra Pharma's over-the-counter (OTC) pain reliever, Nyloxin(R), has begun airing television commercials as of Monday, June 23rd. The advertisements focus on the benefits of Nyloxin(R). The first contract has already begun and includes over 30,000 spots to run throughout the Southeast Region from Comcast and AT&T U-Verse Cable providers. The ads are scheduled to run on the following channels: GOLF, LMN, CNBC, FOXN, MSNBC, NBCS, ESPN, ESPN2, TNT, FOXS, TWC, CNN, HALL, HGTV, TLC, HLN and LIFE. Starting June 30, the commercials will begin airing in the New York and New Jersey markets with a rollout to the national stage in the coming weeks.
Nutra Pharma Announces Completion of Commercials by MyNyloxin.com
Marketwire - Wed Jun 25, 8:25AM CDT
Nutra Pharma Corp. (OTC: NPHC), a biotechnology company that is developing treatments for Adrenomyeloneuropathy (AMN), HIV and Multiple Sclerosis (MS), is announcing that MyNyloxin.com, a new company that has the exclusive rights to market and distribute Nutra Pharma's over-the-counter (OTC) pain reliever, Nyloxin(R), in the Network Marketing channel has completed their work on a series of commercials to start airing in the month of June. The advertisements focus on the benefits of Nyloxin(R) and include 30 second, 60 second and 120 second spots.
Global Amyotrophic Lateral Sclerosis Market 2014-2018: Advanced New Discoveries and Treatments Sheds Light on Factors Involved In ALS
M2 - Thu Feb 13, 6:39AM CST
Research and Markets (http://www.researchandmarkets.com/research/3qv6rf/global) has announced the addition of the "Global Amyotrophic Lateral Sclerosis Market 2014-2018" report to their offering. The analysts forecast the Global Amyotrophic Lateral Sclerosis Drugs Market to grow at a CAGR of 5.39 percent over the period 2013-2018. One of the key factors contributing to this market growth is the increasing global aging population. The Global Amyotrophic Lateral Sclerosis Drugs Market has also been witnessing the increasing awareness of ALS drugs. However, the patent expiry of Rilutek could pose a challenge to the growth of this market. Key vendors dominating this space include Covis Pharmaceutical Inc., Eisai Co. Ltd., GlaxoSmithKline plc, and Mitsubishi Tanabe Pharma Corp. Other vendors mentioned in the report are Amorfix Life Sciences Ltd., BrainStrom Cell Therapeutics Inc., Newron Pharmaceuticals S.p.A, Neuraltus Pharmaceuticals Inc., Nutra Pharma Corp., Oxford BioMedica plc, Pharnext SAS, and Q-Therapeutics Inc. Commenting on the report, an analyst from the team said: The acceptability of ALS drugs is expected to rise due to increasing public awareness of ALS and associated disorders. This is expected to result in increasing drug penetration. Rising general awareness about ALS has led to an increase in research funding and support for clinical and support services. For instance, May is celebrated as ALS awareness month. The ALS Association strives to involve and engage patients and families in the process of increasing awareness and advocating for legislative changes. Similarly, CDMRP also organizes the ALS Research Program. The global research effort through this program has helped increase the number of scientists working on ALS, advanced new discoveries and treatments, and has shed light on the complex genetic and environmental factors involved in ALS. According to the report, one of the main drivers in this market is the increase in the aging population. The number of patients suffering from ALS is increasing due to its relatively high prevalence in the elderly population. For more information visit http://www.researchandmarkets.com/research/3qv6rf/global About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
GSK: 45.74 (+0.08)
New IGP Sets His Priorities, Warns Unethical Officers
by Abdulwakil Saiboko - All Africa Global Media - Thu Jan 09, 10:36PM CST
THE newly-appointed Inspector- General of Police (IGP), Mr Ernest Mangu, has outlined his priorities, warning police over unethical behaviour, saying severe measures will be taken against violators.
SGYP: 3.00 (-0.07), CVM: 0.65 (+0.04), GSK: 45.74 (+0.08), SVA: 5.25 (+0.01), AGEN: 2.98 (unch), VICL: 1.12 (-0.02), FLML: 13.17 (-0.22), MRK: 59.07 (-0.47), NVS: 93.95 (-0.43)
Front Street Energy Growth Fund Inc. Labour Sponsored Fund-Suspension of Redemptions
Marketwire Canada - Fri Dec 20, 1:44PM CST
Due to the 2013 federal government budget announcement that it is discontinuing the Labour Sponsored Venture Capital Corporation ("LSVCC"
program, Front Street Capital 2004 (the "Manager" has announced it is considering options with respect to the labour sponsored fund it manages, Front Street Energy Growth Fund Inc. (the "Fund" . Nutra Pharma Provides Update on Inventory and Fulfillment
Business Wire - Wed Sep 11, 7:30AM CDT
Nutra Pharma Corporation (OTCQB: NPHC), a biotechnology company that is developing treatments for Multiple Sclerosis (MS), Human Immunodeficiency Virus (HIV), Adrenomyeloneuropathy (AMN) and Pain, announced today that they have completed the process of moving their inventory of their all-natural, non-addictive pain reliever, Nyloxin(R), into their Plantation, Florida facility and that they will be handling fulfillment services in-house.
Amyotrophic Lateral Sclerosis - Pipeline Review, H2 2013 comes Complete with Latest Updates
M2 - Thu Sep 05, 10:04AM CDT
Research and Markets (http://www.researchandmarkets.com/research/kg6q26/amyotrophic) has announced the addition of the "Amyotrophic Lateral Sclerosis - Pipeline Review, H2 2013" report to their offering. Global Markets Direct's, 'Amyotrophic Lateral Sclerosis - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Amyotrophic Lateral Sclerosis and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Amyotrophic Lateral Sclerosis. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - A snapshot of the global therapeutic scenario for Amyotrophic Lateral Sclerosis. - A review of the Amyotrophic Lateral Sclerosis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Amyotrophic Lateral Sclerosis pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Mentioned: - Aeolus Pharmaceuticals, Inc. - Amorfix Life Sciences Ltd. - Biogen Idec Inc. - BrainStorm Cell Therapeutics Inc. - California Stem Cell, Inc. - Cellceutix Corporation - Ceregene, Inc. - Cytokinetics, Inc - D-Pharm Ltd. - Daval International Ltd. - Eisai Co., Ltd. - Genzyme Corporation - GlaxoSmithKline plc - Hadasit Medical Research Services & Development Ltd - Isis Pharmaceuticals, Inc. - Isotechnika Pharma Inc. - Jeil Pharmaceutical Co., Ltd. - KineMed, Inc. - Kringle Pharma, Inc. - M's Science Corporation - Maas Biolab - MediPost Co., Ltd. - miRagen Therapeutics, Inc. - Mitsubishi Tanabe Pharma Corporation - Neuralstem, Inc. - Neuraltus Pharmaceuticals, Inc. - Neurimmune Therapeutics AG - NeuroNova AB - Nexgenix Pharmaceuticals, LLC - Novartis AG - Nutra Pharma Corporation - Oxford BioMedica plc - Paladin Labs Inc. - Pharmagenesis, Inc. - Pharnext SAS - Q Therapeutics, Inc. - Questcor Pharmaceuticals, Inc. - Reata Pharmaceuticals, Inc. - RhinoCyte, Inc. - SCYNEXIS, Inc. - Snowdon Inc. - Trophos SA - Varinel, Inc. For more information visit http://www.researchandmarkets.com/research/kg...myotrophic About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
CYTK: 4.23 (-0.01), BIIB: 305.43 (-12.55), GSK: 45.74 (+0.08), BCLI: 3.47 (-0.11), QCOR: 93.60 (+1.52), ISIS: 49.01 (-1.70), NVS: 93.95 (-0.43), CUR: 2.86 (+0.05)
Nutra Pharma Announces Delivery of Nyloxin(TM) to New Vitality
Business Wire - Thu Aug 29, 7:30AM CDT
Nutra Pharma Corporation (OTCQB:NPHC), a biotechnology company that is developing treatments for Multiple Sclerosis (MS), Human Immunodeficiency Virus (HIV), Adrenomyeloneuropathy (AMN) and Pain, announced today that New Vitality, a marketing and distribution company, has placed and received their first order of the Company's all-natural, non-addictive pain reliever, Nyloxin(R). The order was pursuant to New Vitality's successful test radio campaign to gauge the market acceptance of the product.
Nutra Pharma Corporation begins registration process in South Africa of homeopathic pain drug Nyloxin
M2 - Fri Aug 23, 4:09AM CDT
Biotechnology company Nutra Pharma Corporation (OTC Markets:NPHC) reported on Thursday the start of the registration process in South Africa of its homeopathic chronic pain drug Nyloxin.
